Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Circumventing Resistance to Kinase-Inhibitor Therapy

14 Jun 2006

Abstract excerpt

Throughout its history, chronic myeloid leukemia (CML) has set precedents for cancer research and therapy, ranging from the identification of the first specific chromosomal abnormality associated with cancer to the development of imatinib as a specific, targeted therapy for the disease.1 In this issue of the Journal, two articles2,3 continue this tradition by describing how an understanding of resistance to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Eosinophilic Disorders and Syndromes
Share to Chronic Lymphocytic Leukemia Research
Share to Chronic Myeloid Leukemia Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 16775240
DOI: 10.1056/nejme068073

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Circumventing Resistance to Kinase-Inhibitor TherapyPMID 16775240Read ↗

Overcoming kinase resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Tyrosine kinase inhibitors: the first decade.Semantic proximity Read ↗

Mechanisms underlying therapeutic resistance of tyrosine kinase inhibitors in chronic myeloid leukemiaSemantic proximity Read ↗

Mechanisms of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia and recent therapeutic strategies to overcome resistanceSemantic proximity Read ↗

ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.Semantic proximity Read ↗

New directions in the treatment of imatinib failure and/or resistance.Semantic proximity Read ↗

Mechanisms of drug resistance in kinasesSemantic proximity Read ↗

Seeking the causes and solutions to imatinib-resistance in chronic myeloid leukemia.Semantic proximity Read ↗

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read ↗

Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.Semantic proximity Read ↗

Mechanisms of Resistance to ABL Kinase Inhibition in Chronic Myeloid Leukemia and the Development of Next Generation ABL Kinase Inhibitors.Semantic proximity Read ↗

Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.